US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

iShares Genomics Immunology and Healthcare ETF

40.42

-0.4600-1.13%

Pre-market: 40.40-0.0168-0.04%07:01 EDT

Volume:85.59K

Turnover:3.43M

Market Cap:301.13M

PE:- -

High:40.43

Open:40.36

Low:39.72

Close:40.88

52wk High:43.44

52wk Low:23.90

Shares:7.45M

Float Shares:7.45M

Volume Ratio:0.47

T/O Rate:1.15%

Dividend:0.28

Dividend Rate:0.70%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Is Rare Disease Approval Altering The Investment Case For Incyte (INCY)?

Simply Wall St.

Everest Medicines Appoints Ex-Moderna Executive Lakshmi Srinivasan as Head of Translational Medicine

RBC Capital Remains a Hold on Moderna (MRNA)

Vertex to Raise Up to C$7 Million in Subordinated Loan with Attached Warrants

Press Release: Vertex Resource GROUP LTD. Announces Subordinated TERM LOAN of up to C$7,000,000

Xortx Therapeutics outlines anticipated clinical trial application for XRx-026

RBC would be buyers of Revolution Medicines after FDA docs ‘overreaction’

Revolution Medicines selloff ‘overdone and misguided,’ says TD Cowen

Revolution Medicines Falls on Pancreatic Cancer Drug Data Concerns

Revolution trading down after daraxonrasib review docs, says Stifel

Cboe data shows mixed options sentiment in Moderna with shares down 0.56%

CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026

Incyte Updates Financial Calendar with Third-Quarter Results Conference Call and Webcast Schedule

Jefferies Initiates Twist Bioscience at Hold With $150 Price Target

MT Newswires Live

Editas Medicine receives approval to initiate clinical trial of EDIT-401

Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia

Will Phase 3 Trial Start Change Revolution Medicines (RVMD) Narrative

Simply Wall St.

HanchorBio's Subsidiary Seeks Taiwan Nod for Solid Tumor Treatment

MT Newswires Live

Twist Bioscience Corporation : Jefferies Initiates Coverage with Hold Rating; Target Price $150

THOMSON REUTERS

Trading DAY-Stocks, Bonds in Delicate Dance

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au.etasphere.com/stock/IDNA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"IDNA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IDNA\",,,,,undefined,":{"symbol":"IDNA","market":"US","secType":"STK","nameCN":"iShares Genomics Immunology and Healthcare ETF","latestPrice":40.42,"timestamp":1791489600000,"preClose":40.88,"halted":0,"volume":85591,"hourTrading":{"tag":"盘前","latestPrice":40.4032,"preClose":40.42,"latestTime":"07:01 EDT","volume":1,"amount":40.4032,"timestamp":1791543676302,"change":-0.0168,"changeRate":-0.000416,"amplitude":0},"delay":0,"changeRate":-0.011252446183953053,"floatShares":7450000,"shares":7450000,"eps":0,"marketStatus":"Pre-Mkt","change":-0.46,"latestTime":"10-09 07:12:15 EDT","open":40.36,"high":40.43,"low":39.72,"amount":3429583.43904,"amplitude":0.017368,"askPrice":54.27,"askSize":100,"bidPrice":35.56,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1791552600000},"marketStatusCode":1,"adr":0,"exchange":"ARCA","adjPreClose":40.42,"sharesOutstanding":5100000,"nav":40.752915,"aum":307684508.25,"dividendRate":0.006977,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":40.4032,"preClose":40.42,"latestTime":"07:01 EDT","volume":1,"amount":40.4032,"timestamp":1791543676302,"change":-0.0168,"changeRate":-0.000416,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":40.42,"preClose":40.42,"latestTime":"19:56 EDT","volume":5346,"amount":216103.66,"timestamp":1791503775220,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.4660522394556619,"impliedVol":0.1441,"impliedVolPercentile":0.34},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IDNA\",,,,,undefined,":{"symbol":"IDNA","floatShares":7450000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.4660522394556619,"shares":7450000,"dividePrice":0.282,"high":40.43,"amplitude":0.017368,"preClose":40.88,"low":39.72,"week52Low":23.9,"pbRate":"--","week52High":43.44,"institutionHeld":0,"latestPrice":40.42,"eps":0,"divideRate":0.006977,"volume":85591,"delay":0,"ttmEps":0,"open":40.36,"prevYearClose":26.19,"prevWeekClose":41.65,"prevMonthClose":42.32,"prevQuarterClose":42.32,"fiveDayClose":41.64,"twentyDayClose":37.88,"sixtyDayClose":33.12},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IDNA\",params:#limit:5,,,undefined,":[{"date":"2026-06-15","symbol":"IDNA","amount":0.125421,"announcedDate":"2026-06-12","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-15","defaultRemindTime":1781530200000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-18","payableDate":"2026-06-15","currency":"USD","dateTimestamp":1781496000000,"payDate":"2026-06-18"},{"date":"2025-12-16","symbol":"IDNA","amount":0.155456,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2025-06-16","symbol":"IDNA","amount":0.152909,"announcedDate":"2025-06-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-16","defaultRemindTime":1750080600000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-20","payableDate":"2025-06-16","currency":"USD","dateTimestamp":1750046400000,"payDate":"2025-06-20"},{"date":"2024-12-17","symbol":"IDNA","amount":0.11105,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-20","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-20"},{"date":"2024-06-11","symbol":"IDNA","amount":0.11144,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-11","defaultRemindTime":1718112600000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-17","payableDate":"2024-06-11","currency":"USD","dateTimestamp":1718078400000,"payDate":"2024-06-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IDNA\",market:\"US\",,,undefined,":[{"executeDate":"2019-12-16","recordDate":"2019-12-17","paymentDate":"2019-12-20","value":0.237063,"currency":"USD"},{"executeDate":"2020-06-15","recordDate":"2020-06-16","paymentDate":"2020-06-19","value":0.083667,"currency":"USD"},{"executeDate":"2020-12-14","recordDate":"2020-12-15","paymentDate":"2020-12-18","value":0.036209,"currency":"USD"},{"executeDate":"2021-06-10","recordDate":"2021-06-11","paymentDate":"2021-06-16","value":0.052145,"currency":"USD"},{"executeDate":"2021-12-13","recordDate":"2021-12-14","paymentDate":"2021-12-17","value":0.256358,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IDNA\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IDNA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2674383198","title":"Is Rare Disease Approval Altering The Investment Case For Incyte (INCY)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2674383198","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674383198?lang=en_us&edition=fundamental","pubTime":"2026-10-09 10:36","pubTimestamp":1791513417,"startTime":"0","endTime":"0","summary":"Incyte and Mirum Pharmaceuticals reported that the U.S. FDA previously approved Atebrioz (zilurgisertib), an oral ALK2 inhibitor for Fibrodysplasia Ossificans Progressiva in patients aged 12 and older, and granted Incyte a Rare Pediatric Disease Priority Review Voucher.\nThe approval of Atebrioz adds a rare disease product and a transferable FDA voucher to Incyte’s toolkit. This development could influence how the business funds and prioritizes its planned shift toward a broader,...","market":"sg","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-incy/incyte/news/is-rare-disease-approval-altering-the-investment-case-for-in","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-incy/incyte/news/is-rare-disease-approval-altering-the-investment-case-for-in","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","INCY","BK4585","IDNA","BK4532","BK4139","BK4550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674049884","title":"Everest Medicines Appoints Ex-Moderna Executive Lakshmi Srinivasan as Head of Translational Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2674049884","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674049884?lang=en_us&edition=fundamental","pubTime":"2026-10-09 10:13","pubTimestamp":1791512025,"startTime":"0","endTime":"0","summary":"Everest Medicines appoints ex-Moderna executive Lakshmi Srinivasan as head of translational medicineEverest Medicines appointed Lakshmi Srinivasan as senior vice president, head of translational medic","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261009:nNDL9xdVL5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","GNOM","MRNX","BK4568","BK4551","BK1161","MRNY","BK4534","WDNA","BK1574","BK4548","BK4532","BK4501","01952","BK1583","LGHT","MRNA","BK4585","IDNA","BK4533"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674882317","title":"RBC Capital Remains a Hold on Moderna (MRNA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2674882317","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674882317?lang=en_us&edition=fundamental","pubTime":"2026-10-09 09:47","pubTimestamp":1791510478,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Luca Issi maintained a Hold rating on Moderna yesterday and set a price target of $130.00. According to TipRanks, Issi is an an...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-remains-a-hold-on-moderna-mrna-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-remains-a-hold-on-moderna-mrna-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4548","BK4551","LU0128525929.USD","GNOM","BK4139","BK4207","BK4568","IDNA","LU0708994859.HKD","LU1267930573.SGD","LU0029864427.USD","LU0310800379.SGD","BK4534","BK4588","GSIB","MRNA","BK4585","BK4533","LGHT","WDNA","BK4532","BK4501","MRNX","MRNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674886821","title":"Vertex to Raise Up to C$7 Million in Subordinated Loan with Attached Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2674886821","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674886821?lang=en_us&edition=fundamental","pubTime":"2026-10-09 07:38","pubTimestamp":1791502698,"startTime":"0","endTime":"0","summary":"An update from Vertex Resource Group Ltd. ( ($TSE:VTX) ) is now available. Vertex Resource Group Ltd., a North American environmental services firm...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vertex-to-raise-up-to-c7-million-in-subordinated-loan-with-attached-warrants?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vertex-to-raise-up-to-c7-million-in-subordinated-loan-with-attached-warrants?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1035775433.USD","LU0432979614.USD","BK4585","IE00BJT1NW94.SGD","LU1093756168.USD","SG9999001176.USD","LU1674673428.USD","LU2362541513.USD","IE00B19Z9P08.USD","IE00B19Z3581.USD","LU2362541273.HKD","IBBQ","LU1778281490.HKD","BIB","LU0256863811.USD","LU0757428866.USD","LU1430594728.SGD","TBXU","LU0823416689.USD","LU2417539215.USD","BK4532","VRTX","IDNA","IE00B894F039.SGD","LU2237438978.USD","BBH","BK4567","IE00B19Z3B42.SGD","PBE","IE00B4R5TH58.HKD","LU1815336091.USD","LU0058720904.USD","LU0417517546.SGD","IE00B2B36J28.USD","LU1559883803.SGD","SGXZ57979304.SGD","GNMX","SG9999013999.USD","LU2089984988.USD","BK4588","LU2462157665.USD","LU2456880835.USD","BK4139","IE0009355771.USD","IBB","VERX","IE0002141913.USD","LU0061475181.USD","LU0566484027.USD","LU2468319806.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674883067","title":"Press Release: Vertex Resource GROUP LTD. Announces Subordinated TERM LOAN of up to C$7,000,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2674883067","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674883067?lang=en_us&edition=fundamental","pubTime":"2026-10-09 06:30","pubTimestamp":1791498600,"startTime":"0","endTime":"0","summary":"SHERWOOD PARK, AB, Oct. 8, 2026 /CNW/ -- (TSXV: VTX) -- Vertex Resource Group Ltd. (\"Vertex\" or the \"Corporation\") announces its intention to enter into a subordinated credit arrangement with Factory ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0432979614.USD","LU1674673691.USD","LU1674673428.USD","IBBQ","IE00B4R5TH58.HKD","SG9999001176.SGD","91013","BBH","IE00B19Z9Z06.USD","LU2462157665.USD","LU0889565916.HKD","VRTX","LU0061475181.USD","BK4567","LU1093756325.SGD","LU2362540622.SGD","IDNA","IE00BJT1NW94.SGD","LU2237438978.USD","IE0002141913.USD","BK4585","LU0289739699.SGD","BK4533","LU1778281490.HKD","LU2417539215.USD","VERX","PBE","BK4588","LU0079474960.USD","LU2362541273.HKD","SG9999001176.USD","TBXU","91512","IE0009355771.USD","LU0320765992.SGD","LU1585245621.USD","SGXZ57979304.SGD","IE00B894F039.SGD","IE0002270589.USD","GNMX","BIB","IBB","BK4139","LU0757428866.USD","LU2468319806.SGD","SG9999013999.USD","IE00BZ9MQY76.HKD","LU0109394709.USD","LU2456880835.USD","LU0566484027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674000503","title":"Xortx Therapeutics outlines anticipated clinical trial application for XRx-026","url":"https://stock-news.laohu8.com/highlight/detail?id=2674000503","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674000503?lang=en_us&edition=fundamental","pubTime":"2026-10-09 04:05","pubTimestamp":1791489913,"startTime":"0","endTime":"0","summary":"Xortx Therapeutics (XRTX) provided an outline of its anticipated clinical trial application, or CTA, submission to Health Canada for the XRx-026 go...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/xortx-therapeutics-outlines-anticipated-clinical-trial-application-for-xrx-026-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/xortx-therapeutics-outlines-anticipated-clinical-trial-application-for-xrx-026-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4539","HYLG","IDNA","MEDX","GDOC","CTA","NVIB","JPFP","DBMF","SDMF","BK4139","ISMF","LENZ","XRTX","TFPN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674074190","title":"RBC would be buyers of Revolution Medicines after FDA docs ‘overreaction’","url":"https://stock-news.laohu8.com/highlight/detail?id=2674074190","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674074190?lang=en_us&edition=fundamental","pubTime":"2026-10-09 03:45","pubTimestamp":1791488724,"startTime":"0","endTime":"0","summary":"RBC Capital notes Revolution Medicines (RVMD) looks to be down in response to yesterday’s disclosure of FDA’s Rasonque review documents, particular...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rbc-would-be-buyers-of-revolution-medicines-after-fda-docs-overreaction-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rbc-would-be-buyers-of-revolution-medicines-after-fda-docs-overreaction-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBH","IE0009355771.USD","IE00B4R5TH58.HKD","GSIB","LABU","LU0889565916.HKD","IE00BJJMRZ35.SGD","IE0002141913.USD","LU0310800379.SGD","LU0708994859.HKD","BK4139","LU0109394709.USD","LU0029864427.USD","PTH","IE00BJT1NW94.SGD","RVMD","IE0009354923.USD","LU0320765992.SGD","BK4588","IDNA","IE00B2B36J28.USD","LU0128525929.USD","BK4207","BK4585","LU1267930573.SGD","CANC","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674077820","title":"Revolution Medicines selloff ‘overdone and misguided,’ says TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2674077820","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674077820?lang=en_us&edition=fundamental","pubTime":"2026-10-09 03:40","pubTimestamp":1791488425,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Tyler Van Buren reiterated a Buy rating on Revolution Medicines (RVMD), saying Thursday’s selloff on Rasonque’s reported efficacy ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/revolution-medicines-selloff-overdone-and-misguided-says-td-cowen-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/revolution-medicines-selloff-overdone-and-misguided-says-td-cowen-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0002141913.USD","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","COWN","BBH","LU0109394709.USD","IE0009354923.USD","BK4127","IE00B2B36J28.USD","IDNA","IE00BFTCPJ56.SGD","CANC","LU0320765992.SGD","LU0889565916.HKD","PTH","IE0009355771.USD","BK4139","RVMD","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674004785","title":"Revolution Medicines Falls on Pancreatic Cancer Drug Data Concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=2674004785","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674004785?lang=en_us&edition=fundamental","pubTime":"2026-10-09 02:17","pubTimestamp":1791483427,"startTime":"0","endTime":"0","summary":"BUZZ-Revolution Medicines falls on pancreatic cancer drug data concerns** Shares of Revolution MedicinesRVMD.Odown 8.1% at $185.91 in afternoon trading** RBC Capital Markets says stock looks to be dow","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nL4N45U1II:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBH","RVMD","CANC","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","BK4139","IE0002141913.USD","LU0889565916.HKD","LU0109394709.USD","IE00BJJMRZ35.SGD","LU0320765992.SGD","IE0009355771.USD","PTH","IDNA","IE00B2B36J28.USD","IE0009354923.USD","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674091230","title":"Revolution trading down after daraxonrasib review docs, says Stifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2674091230","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674091230?lang=en_us&edition=fundamental","pubTime":"2026-10-09 00:05","pubTimestamp":1791475557,"startTime":"0","endTime":"0","summary":"Stifel says shares of Revolution Medicines (RVMD) are lower after the FDA posted multidisciplinary review documents for daraxonrasib with additiona...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/revolution-trading-down-after-daraxonrasib-review-docs-says-stifel-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/revolution-trading-down-after-daraxonrasib-review-docs-says-stifel-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0009355771.USD","IE00BJT1NW94.SGD","BK4588","RVMD","BK4585","CANC","IE0009354923.USD","IE00B2B36J28.USD","IE0002141913.USD","BBH","LU0109394709.USD","LU0889565916.HKD","IE00BJJMRZ35.SGD","IDNA","IE00B4R5TH58.HKD","LU0320765992.SGD","LABU","PTH","BK4139","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674009816","title":"Cboe data shows mixed options sentiment in Moderna with shares down 0.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2674009816","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674009816?lang=en_us&edition=fundamental","pubTime":"2026-10-08 23:55","pubTimestamp":1791474923,"startTime":"0","endTime":"0","summary":"Cboe data shows mixed options sentiment in Moderna (MRNA), with shares down $1.11 near $195.37. Options volume relatively light with 36k contracts ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cboe-data-shows-mixed-options-sentiment-in-moderna-with-shares-down-0-56-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cboe-data-shows-mixed-options-sentiment-in-moderna-with-shares-down-0-56-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MRNA","BK4585","BK4532","BK4501","BK4533","BK4548","GNOM","LGHT","WDNA","BK4551","BK4568","IDNA","MRNX","BK4534","BK4588","MRNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673077189","title":"CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2673077189","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673077189?lang=en_us&edition=fundamental","pubTime":"2026-10-08 20:30","pubTimestamp":1791462600,"startTime":"0","endTime":"0","summary":"ZUG, Switzerland and BOSTON, Oct.  08, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that clinical data from the Phase 1b trial of CTX310, its investigational CRISPR/Cas9","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/08/3377269/0/en/crispr-therapeutics-to-present-late-breaking-data-at-the-american-heart-association-aha-scientific-sessions-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861558580.USD","BK4117","LU1861559042.SGD","SYNB","ARKG","AGT","BK4585","AFG","BK4588","BK4556","CRSP","BK4139","BK4107","BK4611","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673074298","title":"Incyte Updates Financial Calendar with Third-Quarter Results Conference Call and Webcast Schedule","url":"https://stock-news.laohu8.com/highlight/detail?id=2673074298","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673074298?lang=en_us&edition=fundamental","pubTime":"2026-10-08 20:01","pubTimestamp":1791460900,"startTime":"0","endTime":"0","summary":"Incyte updates financial calendar with third-quarter results conference call and webcast scheduleIncyte scheduled its Q3 2026 results release for Oct. 29, 2026, at 7:00 a.m. ET.Management will host th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nNDLbL9kYp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4550","INCY","BK4139","BK4532","BK4585","IDNA","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673507199","title":"Jefferies Initiates Twist Bioscience at Hold With $150 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2673507199","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673507199?lang=en_us&edition=fundamental","pubTime":"2026-10-08 19:28","pubTimestamp":1791458909,"startTime":"0","endTime":"0","summary":"Twist Bioscience (TWST) has an average rating of overweight and mean price target of $150.33, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GNOM","WDNA","ARKG","BK4585","BK4588","BK4139","TWST","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673071338","title":"Editas Medicine receives approval to initiate clinical trial of EDIT-401","url":"https://stock-news.laohu8.com/highlight/detail?id=2673071338","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673071338?lang=en_us&edition=fundamental","pubTime":"2026-10-08 19:06","pubTimestamp":1791457602,"startTime":"0","endTime":"0","summary":"Editas Medicine (EDIT) announced it has received approval to initiate the Phase 1/2 Strive clinical trial of EDIT-401 in patients with Heterozygous...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/editas-medicine-receives-approval-to-initiate-clinical-trial-of-edit-401-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/editas-medicine-receives-approval-to-initiate-clinical-trial-of-edit-401-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIB","BK4556","IDNA","EDIT","BK4139","MEDX","HYLG","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673714960","title":"Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2673714960","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673714960?lang=en_us&edition=fundamental","pubTime":"2026-10-08 19:00","pubTimestamp":1791457200,"startTime":"0","endTime":"0","summary":"Phase 1/2 clinical trial of EDIT-401 cleared to initiate dosing in patients who require additional LDL-C lowering Company remains on track to begin patient dosing this year and report initial safety a","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/08/3377124/0/en/editas-medicine-receives-approval-to-initiate-first-in-human-clinical-trial-of-edit-401-in-patients-with-hyperlipidemia.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDNA","MEDX","HYLG","SYNB","GDOC","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673017021","title":"Will Phase 3 Trial Start Change Revolution Medicines (RVMD) Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2673017021","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673017021?lang=en_us&edition=fundamental","pubTime":"2026-10-08 15:26","pubTimestamp":1791444398,"startTime":"0","endTime":"0","summary":"Revolution Medicines has already started treating patients in RASolute 309, a global Phase 3 trial testing RASONQUE plus zoldonrasib as first line therapy against standard gemcitabine and nab paclitaxel in metastatic RAS G12D pancreatic cancer, with progression free and overall survival as dual primary endpoints.\nThe study targets RAS G12D, the most prevalent RAS mutation across cancers, where roughly 61,000 new U.S. patients each year currently have no approved targeted therapy. This puts...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rvmd/revolution-medicines/news/will-phase-3-trial-start-change-revolution-medicines-rvmd-na","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rvmd/revolution-medicines/news/will-phase-3-trial-start-change-revolution-medicines-rvmd-na","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0889565916.HKD","IE00B4R5TH58.HKD","BK4139","LU2298322129.HKD","BK4512","LU1861219969.SGD","BK4141","IE0002141913.USD","LU1548497426.USD","ONG","IE00BFTCPJ56.SGD","CANC","LU1861215975.USD","ON","LU1720051017.SGD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","LU2357305700.SGD","LU1720051108.HKD","LU1854103824.USD","LU0124384867.USD","BK4588","IE0009355771.USD","IE00BZ199S13.USD","LU0348723411.USD","LU0724618433.USD","IDNA","PTH","LU2360107325.USD","LU1861214812.USD","LU0320765992.SGD","IE0009354923.USD","ONX","LU1854104046.USD","RVMD","BK4605","LU1983260115.SGD","BBH","LU1861220033.SGD","IE00BFMHRM44.USD","LU0109394709.USD","IE00BD6J9T35.USD","LU1978683503.SGD","BK4585","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673040775","title":"HanchorBio's Subsidiary Seeks Taiwan Nod for Solid Tumor Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2673040775","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673040775?lang=en_us&edition=fundamental","pubTime":"2026-10-08 12:43","pubTimestamp":1791434637,"startTime":"0","endTime":"0","summary":"HanchorBio's  subsidiary, FBD Biologics, has submitted an Investigational New Drug application to the Taiwan Food and Drug Administration  for clinical trial review of HCB303, a trispecific fusion protein being developed for the potential treatment of solid tumors.The application follows the recent receipt of approval from the U.S. Food and Drug Administration for HCB303, according to a Wednesday filing to the Taiwan Stock Exchange.TFDA approval and applicable institutional ethics approval will pave the way for patient enrollment for the trial in Taiwan.Following receipt of the required regulatory and institutional ethics approvals, the company plans to conduct Phase I, Phase II, and Phase III clinical trials sequentially.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IDNA","GDOC","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673047449","title":"Twist Bioscience Corporation : Jefferies Initiates Coverage with Hold Rating; Target Price $150","url":"https://stock-news.laohu8.com/highlight/detail?id=2673047449","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673047449?lang=en_us&edition=fundamental","pubTime":"2026-10-08 11:44","pubTimestamp":1791431098,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nFWN45U00I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4588","TWST","BK4139","GNOM","IDNA","ARKG","WDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673048285","title":"Trading DAY-Stocks, Bonds in Delicate Dance","url":"https://stock-news.laohu8.com/highlight/detail?id=2673048285","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673048285?lang=en_us&edition=fundamental","pubTime":"2026-10-08 05:00","pubTimestamp":1791406800,"startTime":"0","endTime":"0","summary":"TRADING DAY-Stocks, bonds in delicate danceORLANDO, Florida, Oct 7 (Reuters)-A sea of red swept across globalstockson Wednesday as the bond market selloff picked up again and lifted long-dated US yiel","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261007:nL6N45T104:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","LU0210536198.USD","LU1435385759.SGD","LU2237443895.HKD","LU2237438978.USD","LU0820561818.USD","LU0094547139.USD","LU0097036916.USD","NVDB","AIPI","LU0234570918.USD","LU2505996681.GBP","LU2458330243.SGD","LU1066053197.SGD","HK0000532082.HKD","LU2133065610.SGD","LU0708995401.HKD","LU2430703178.SGD","LFGY","LU2360032135.SGD","LU2168564495.EUR","LU2065171402.SGD","ESLG","LU2125909247.SGD","LU2637965513.SGD","LU0786609619.USD","LU2357305700.SGD","SPTE","NVDY","SNPE","IE00BJTD4V19.USD","IE00BK4W5L77.USD","IE00BQXX3C00.GBP","LU1037948541.HKD","LU1670756490.USD","LU2286300806.USD","LU2417539215.USD","BK4149","NULC","LU0689472784.USD","LU2360107168.USD","ANV","LU0225283273.USD","LU1861127337.USD","LU1267930573.SGD","LU2237957811.SGD","FDTX","LU1267930490.SGD","LU2063271972.USD","LU0079474960.USD","LU2083900584.USD","LU2462591350.SGD","IE00BK4W5M84.HKD","LU0256863902.USD","LU1989772923.USD","LU2271345857.HKD","SGXZ81514606.USD","LU2023250504.SGD","LU0072462426.USD","ABFL","LU0820562030.AUD","LU2552382132.HKD","LU2237957902.USD","LU0889565833.HKD","LU0861579265.USD","LU0965509283.SGD","LU0742534661.SGD","LU2860962120.EUR","LU2237443978.SGD","LU0787776722.HKD","LU1712237335.SGD","LU0942090050.USD","LU1316542783.SGD","IE00BJJMRY28.SGD","LU0154236417.USD","MUZ","SG9999014559.SGD","FAI","LU2023250330.USD","GAMR","BK4527","LU0174119429.USD","LU0957808578.USD","IE0004445239.USD","LU2054465674.USD","LU1934455863.HKD","NVDA","IE0034235295.USD","SMH","BK4566","LU1069347547.HKD","SMHX","LU0211327993.USD","PSI","LU2552382215.SGD","LU2756315664.SGD","LU1119994496.HKD","BK4534","BK4141","LU1267930813.SGD","SG9999014914.USD","SG9999014542.SGD","TTEQ","LU0158827781.USD","LU1732799900.SGD","LU1242518931.SGD","DIPS","LU2543165471.USD","LU1951198990.SGD","SPCQ","LU1923622291.USD","NVYY","BK4608","HWAY","LU2896262040.SGD","LU0203202063.USD","DSPC","IE0004091025.USD","LU2237443465.HKD","IE00BYXW3230.USD","ORBX","LU0965509010.AUD","IE00BQXX3F31.USD","NVII","NVDO","LU2360106780.USD","IE00B19Z8W00.USD","LU0345769128.USD","SPCH","BK4579","LU2023251221.USD","LU1989772840.SGD","LU2463028550.USD","ILDR","LU0957791311.USD","LU2097344357.USD","AGOX","WUGI","IETC","NVD3.UK","LU2592432038.USD","IE00BQXX3D17.EUR","LU2462591277.SGD","LU1951200564.SGD","BK4501","EMSF","LU0868494617.USD","LU2108987350.USD","IE00B5949003.HKD","SG9999001424.SGD","LU0882574139.USD","USD","WARP","LU2168563687.JPY","SG9999014567.USD","IE00B19Z3581.USD","LU0203345920.USD","LU1914381329.SGD","LU2211815571.USD","LU2249611893.SGD","IE0009356076.USD","LU0128525929.USD","LU2394011477.USD","USXF","LU1674673691.USD","SGXZ80539844.SGD","LU0724617625.USD","MULL","SNK","IE00BN29S564.USD","IE00B7KXQ091.USD","SOXQ","IE00BFSS7M15.SGD","LU2047632596.USD","IE0034235303.USD","LU0979878070.USD","LU0823414478.USD","SG9999015978.USD","LU2487616109.SGD","LU1633808545.USD","LU0820561909.HKD","LU0210528500.USD","JGRO","LU1935043023.USD","ARTY","IE00B775SV38.USD","LU0070217475.USD","LU2322448957.HKD","TYLG","LU0274383776.USD","IE0001KFT4U8.USD","LU0081259029.USD","LU1935042488.USD","LU1496350171.SGD","LU1674673428.USD","LU0640476718.USD","LU1699723380.USD","XLK","LU2065169927.USD","TRUI","LU0912757837.SGD","LU0823421416.USD","LU0859254822.USD","FTXL","LU2413666426.HKD","IE00BMPRXQ63.HKD","LU0353189763.USD","LU2458330169.SGD","IE00BKDWB100.SGD","LU0175139822.USD","LU2473716301.USD","IE00BD6J9T35.USD","LU0011850046.USD","IE000YTNTUN2.SGD","LU2250418816.HKD","LU0823434583.USD","IE0034235188.USD","DRMY","LU0792757196.USD","SG9999002224.SGD","LU0889566641.SGD","LU0256863811.USD","LU1144417596.USD","LU2242649171.HKD","NVDW","LU1066051811.HKD","TRFK","TTXU","LU0320765059.SGD","LU2602419157.SGD","SPAX","LU1400636657.SGD","GASZ","SGXZ23171101.USD","IE000W1ABFV2.USD","LU2087621335.USD","IE00B1XK9C88.USD","LU1861215975.USD","LU2065171311.SGD","LU2931357623.SGD","MRNX","LU0964807845.USD","LU1069344957.HKD","ESUM","LU1035773651.USD","LU0187121727.USD","LU0265550359.USD","NVDX","LU2290526834.HKD","EFIV","BK4503","LU1992135399.USD","BK4529","RULE","LU1732800096.USD","NVIW.SI","LU0069063385.USD","LU2125154778.USD","ROM","LU1244550494.USD","LU0345768740.USD","IE000ITXATA3.USD","LU2168564065.EUR","IE00B775H168.HKD","LU0390134368.USD","LU2168564222.USD","WSPC","IE00B19Z3B42.SGD","LU0170899867.USD","LU0080751232.USD","LU1548497426.USD","IE00BKPKM429.USD","TEK","IE0003U64NQ7.SGD","LU2125909593.SGD","SPCM","VT","BK4512","BK4550","LU0267386448.USD","LU0323240290.USD","MUYY","IE00BJJMRX11.SGD","LU0048584097.USD","LU1868837136.USD","LU2452424414.USD","CNEQ","LU0251132253.USD","BK4612","LU1145028129.USD","NVD2.UK","CATG","NVD","LU2213496289.HKD","BK4548","LU0354030438.USD","LU2100268510.USD","LU0203201768.USD","NVDG","3NVD.UK","LU0348723411.USD","LU0898699433.AUD","LU0545039389.USD","LU2357125470.USD","LU1642822529.SGD","LU2028103732.USD","SG9999014906.USD","SG9999014898.SGD","LOFD","LU0417517546.SGD","IE000Q6AESB8.SGD","LU1868836914.USD","LU1720051108.HKD","LU2102340556.USD","UXI","LU1814569148.SGD","LU0683600562.USD","NVDS.UK","LU0061475181.USD","IE0009G5SDU7.USD","NVDD","LU0661504455.SGD","LU0251131958.USD","LU2272731865.HKD","LU2746668461.USD","LU2746668974.SGD","LU0006306889.USD","LU1934455277.USD","LU2471134523.USD","LU0823414551.USD","LU2089284900.SGD","LU1127390331.HKD","BK4532","LU1037948897.HKD","LU1868837300.USD","SG9999015945.SGD","LU2237443622.USD","07388","BOBP","HK0000304805.HKD","LU1989764664.SGD","LU0210533765.USD","LU2077746001.SGD","LU0943347566.SGD","BK4089","LU1066051225.USD","LU1202635105.USD","LU2471134796.USD","IDNA","LU0347712357.USD","LU1861220033.SGD","LU1974910355.USD","LU0061474960.USD","LU1868836757.USD","LU1880398471.USD","SPCU","LU0203347892.USD","LU0143551892.USD","LU2505996509.AUD","LU2403377893.USD","HK0000306685.HKD","LU2361044865.SGD","IE00BDCRKT87.USD","LU1496350502.SGD","LU0310799852.SGD","LU2097344431.USD","BK4516","09788","MARS","CHAT","BAI","LU0106261372.USD","HK0000304797.USD","NVDL","LU1232071149.USD","LU1803068623.USD","LU0138981039.USD","LU1261432733.SGD","LU2326559502.SGD","LU0965509101.SGD","LU1988902786.USD","AIFD","LU0985320562.USD","LU1803068979.SGD","YSPC","IE0002270589.USD","LU2244417387.USD","LU1804176565.USD","GB00BDT5M118.USD","LU1400636491.USD","LU1323610961.USD","LU2237443382.USD","BK4567","LU0316494557.USD","LU0061474705.USD","IE00BZ199S13.USD","LU0198837287.USD","LU1923622614.USD","BK4588","LU0949170772.SGD","LU0289739343.SGD","LU0109391861.USD","LU2048586759.USD","MRNY","LU1880398554.USD","LU2756315318.SGD","IE00B4YYXB79.USD","LU0276348264.USD","LU1791710582.SGD","LU2456880835.USD","BK4598","09388","LU0345769631.USD","LU0048573561.USD","LU0726765562.USD","VGT","LU0795875169.SGD","LU0133085943.USD","SNVD.UK","LU0077335932.USD","LU1244550577.SGD","MADE","LU1244550221.USD","SGXZ31699556.SGD","WLDR","LU2461242641.AUD","LU0868494708.USD","LU1852331112.SGD","LOFF","LU1035775433.USD","LU2242650005.HKD","MUU","LU1116320901.HKD","CAT","IE00B4JS1V06.HKD","BK4614","BK4568","LU0289960550.SGD","LU1267930730.SGD","LU0082616367.USD","DISK","LU1979441026.SGD","SG9999015952.SGD","IE00B7SZLL34.SGD","LEGR","LU2106854487.HKD","IE00BZ1G4Q59.USD","LU2065170008.USD","LGHT","07788","IE00BFSS8Q28.SGD","LU1868836591.USD","LU1861559042.SGD","SG9999014575.USD","LU2420271590.USD","LU0965508806.USD","LU0096364046.USD","SG9999002232.USD","LU0672654240.SGD","SSPC","BK4554","BK4553","IE00BSNM7G36.USD","WDNA","LU2357627491.SGD","LU1064131342.USD","SG9999000418.SGD","LU2381873111.SGD","LU1003077747.HKD","LU2361045086.USD","LU1066051498.USD","LU0511384066.AUD","LU1934455194.USD","NVDS","LU0211328371.USD","LU2089283258.USD","IE00BWXC8680.SGD","CGGO","LU2506951792.HKD","2NVD.UK","LU0053666078.USD","LU0642271901.SGD","LU1935043536.SGD","CLSE","LU1551013425.SGD","LU0345770993.USD","LU1791710400.SGD","MUG","LU0238689110.USD","LU0528227936.USD","LU2750360641.GBP","LU2279689827.SGD","SPCF","SG9999018865.SGD","LU1691799644.USD","LU2272731600.USD","LU0308772762.SGD","LU2413666699.HKD","THMR","HK0000914686.HKD","LU0354030511.USD","LU1839511570.USD","SG9999015358.SGD","LU0476273544.USD","CHPX","LU2168564149.EUR","LU2092627202.USD","IXN","LU2125909759.SGD","LU2191332357.HKD","SPCX","BK4587","LU0124676726.USD","LU1551013342.USD","ELOL","LU2125154935.USD","SHOC","FTEC","IE000KEQY171.SGD","EXI","LU1116320737.USD","SGXZ99366536.SGD","LU1429558221.USD","MIC","LU0342679015.USD","LU2322448791.USD","SGXZ51526630.SGD","HK0000819398.USD","LU2462157665.USD","LU1815333072.USD","LU2471134879.HKD","SPAL","RSHO","LU0289961442.SGD","LU2433249047.HKD","LU0466842654.USD","LU2087625088.SGD","SNVDAmain","LU1720051017.SGD","MRNA","XNTK","SG9999018857.SGD","SG9999014880.SGD","LU2430703095.HKD","SG9999015341.SGD","LU0472753341.HKD","LU1815336760.USD","LU0823421333.USD","CHPS","HK0000320264.USD","IE00BKVL7J92.USD","SG9999004303.SGD","LU0323239441.USD","LU2430703251.USD","LU2237443549.SGD","LU1989764748.USD","LU2148611432.USD","LU0109392836.USD","IE00B3SWFQ91.USD","BK4549","LU1084165304.USD","LU2092937148.SGD","BK4543","IE00BMPRXN33.USD","LU0345770308.USD","IE00BJTD4N35.SGD","LU2471134952.CNY","IE00B19Z9505.USD","LU0444971666.USD","LU0738911758.USD","LU2552382058.USD","LU0158827948.USD","BK4575","BK4581","MUD","LU0157215616.USD","LU2264538146.SGD","LU1242518857.USD","LU2491050071.SGD","LU1778281490.HKD","LU0395794307.EUR","IE00BMPRXR70.SGD","HK0000306701.USD","LU0056508442.USD","IE0005OL40V9.USD","LU2247934214.USD","LU1366333091.USD","METV","IE00B1BXHZ80.USD","BK4597","LU2294711713.HKD","IE00BDRTCR15.USD","LU0444973449.USD","LU2347655073.USD","LU0553294199.USD","LU0823434740.USD","LU1718418525.SGD","LU1917777945.USD","SOXY","NVDQ","LU0788109477.HKD","SPCG","BK4592","LU1821325948.USD","LU2491050154.USD","BK4533","LU0096362180.USD","LU2347655156.SGD","LU2265009873.SGD","HK0000320223.HKD","LU2111349929.HKD","LU0266013472.USD","LU1923623000.USD","LU0057025933.USD","LU1629891620.HKD","LU0127658192.USD","FXL","HBMX","LU0029864427.USD","IE00BHPRN162.USD","LU0719512351.SGD","LU0251142724.SGD","IE00B19Z8X17.USD","LU0107464264.USD","LU1366192091.USD","LU0795875086.SGD","SG9999015986.USD","LU2361044949.HKD","LU1400636574.HKD","SOXX","PTF","LU1645745479.HKD","LU0708994859.HKD","SG9999017495.SGD","BK4139","LU2999663052.SGD","WISE","NVC","LU2089985449.USD","IE000M9KFDE8.USD","NVDU","LU0310800379.SGD","LU0345768153.USD","LU2272731782.SGD","LU3102509885.SGD","CMAG","LU1935043452.HKD","LU1992135472.HKD","LU1861558580.USD","EGGY","IE00BJLML261.HKD","LU2125909916.SGD","BK4520","HK0000914660.USD","LU0689626769.HKD","BK4585","LU0265550946.USD","LU1623119135.USD","BK4605","LU1983260115.SGD","LU0353189680.USD","MU","LU1280957306.USD","LU0234572021.USD","LU2750360997.AUD","IE00B5TLWC47.USD","LU0215105999.USD","LU2954938101.SGD","LU2491049909.HKD","SMU00main","LU2236285917.USD","LU1935042215.USD","LU1721428933.USD","AIQ","IE0004445015.USD","IE00B3M56506.USD","LU0557290698.USD","LU1571399168.USD","LU0323591593.USD","LU0494093205.USD","LU1153585028.USD","GNOM","AIS","IE0004086264.USD","IE00B3S45H60.SGD","LU1935042991.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}